Q: 腔腸素溶液如何配制？

A: （1）腔腸素溶液配制方式來源文獻，僅供參考，具體工作濃度建議參考文獻做梯度摸索最佳濃度。 母液：稱取 1mg 腔腸素粉末直接溶解于 197µl 酸化的甲醇溶液（ 100% 甲醇中含有  20µl/ml 3M  或者  6M HCl），配制成  12 mM （~5mg/ml,5×） 的腔腸素儲存液。 工作液：如體外：10 的 5 次方的細胞數可用 10 μ M 。

Q:腔腸素的發(fā)光特性如何？

A: 體外：細胞孵育 10-15min 后，立即檢測。 體內：可在注射后 10-15 min 內檢測。

僅供參考，建議預實驗建立熒光素酶動力學曲線，從而確定最高信號檢測時間和信號平臺期。

Q:是否能用于活體成像？

A: 一般用于體外，因為容易氧化，體內的話要注射和麻醉，時間久，體外檢測快，不影響。體內的話推薦即用型。

Q:推薦儀器？多功能酶標儀能用嗎？

A: 推薦儀器：具有生物化學發(fā)光檢測模塊。熒光素產生的光可以被光度計或閃爍計數器檢測。常見的活體成像儀器：如 IVIS® Lumina 小動物活體成像系統(tǒng)，德國 Bruker 公司的 In-Vivo Xtreme 多模式小動物活體成像儀。多功能酶標儀：需要和儀器廠家確認是否具體生物化學發(fā)光檢測模塊。注：不能用熒光顯微鏡。

Q:說明書寫到的配置儲存液用的丙二醇是1,2-丙二醇嗎？乙醇是無水乙醇嗎？

A: 是的，丙二醇是1,2-丙二醇，乙醇是無水乙醇。

[1] Lin S, Han S, Cai X, et al. Structures of G_i-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature. 2021;594(7864):583-588. doi:10.1038/s41586-021-03495-2(IF:49.962)
[2] Ma S, Chen Y, Dai A, et al. Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor. Cell Res. 2021;31(10):1061-1071. doi:10.1038/s41422-021-00557-y(IF:25.617)
[3] Zhang H, Chen LN, Yang D, et al. Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell Res. 2021;31(11):1163-1175. doi:10.1038/s41422-021-00552-3(IF:25.617)
[4] Shao Z, Shen Q, Yao B, et al. Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1. Nat Chem Biol. 2022;18(3):264-271. doi:10.1038/s41589-021-00918-z(IF:15.040)
[5] Liu Q, Yang D, Zhuang Y, et al. Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptor. Nat Chem Biol. 2021;17(12):1238-1244. doi:10.1038/s41589-021-00841-3(IF:15.040)
[6] Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022;13(1):1057. Published 2022 Feb 25. doi:10.1038/s41467-022-28683-0(IF:14.919)
[7] Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. Published 2020 Oct 15. doi:10.1038/s41467-020-18945-0(IF:12.121)
[8] Shao L, Chen Y, Zhang S, et al. Modulating effects of RAMPs on signaling profiles of the glucagon receptor family. Acta Pharm Sin B. 2022;12(2):637-650. doi:10.1016/j.apsb.2021.07.028(IF:11.614)
[9] Shao Z, Tan Y, Shen Q, et al. Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3. Cell Discov. 2022;8(1):44. Published 2022 May 15. doi:10.1038/s41421-022-00403-4(IF:10.849)
[10] Zhao F, Zhang C, Zhou Q, et al. Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor. Elife. 2021;10:e68719. Published 2021 Jul 13. doi:10.7554/eLife.68719(IF:8.146)
[11] Wang YZ, Yang DH, Wang MW. Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors. Acta Pharmacol Sin. 2022;43(6):1453-1460. doi:10.1038/s41401-021-00758-6(IF:6.150)
[12] Wang J, Yang D, Cheng X, et al. Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site. ACS Chem Biol. 2021;16(11):2444-2452. doi:10.1021/acschembio.1c00552(IF:5.100)
[13] Lin GY, Lin L, Cai XQ, et al. High-throughput screening campaign identifies a small molecule agonist of the relaxin family peptide receptor 4. Acta Pharmacol Sin. 2020;41(10):1328-1336. doi:10.1038/s41401-020-0390-x(IF:5.064)
[14] Darbalaei S, Yuliantie E, Dai A, et al. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochem Pharmacol. 2020;180:114150. doi:10.1016/j.bcp.2020.114150(IF:4.960)
[15] Yuliantie E, Darbalaei S, Dai A, et al. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol. 2020;177:114001. doi:10.1016/j.bcp.2020.114001(IF:4.960)
[16] Sun L, Hao Y, Wang Z, Zeng Y. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines. Viruses. 2018;10(4):145. Published 2018 Mar 23. doi:10.3390/v10040145(IF:3.761)